Sanofi's ($SNY) in line to rack up blockbuster sales after hitting a wide-open market with its dengue vaccine, analysts predict. And company CEO Chris Viehbacher thinks those sales could start rolling in before next year is out. Report
Sanofi's ($SNY) in line to rack up blockbuster sales after hitting a wide-open market with its dengue vaccine, analysts predict. And company CEO Chris Viehbacher thinks those sales could start rolling in before next year is out. Report